CNTB
Income statement / Annual
Last year (2024), Connect Biopharma Holdings Limited's total revenue was $26.03 M,
and the percentage change from the previous year is not available.
In 2024, Connect Biopharma Holdings Limited's net income was -$15.63 M.
See Connect Biopharma Holdings Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$26.03 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$988,000.00
|
$1.03 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$26.03 M
|
-$988,000.00
|
-$1.03 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$29.26 M
|
$51.91 M
|
$95.26 M
|
$81.34 M
|
$23.12 M
|
$15.44 M
|
| General & Administrative Expenses |
$19.23 M
|
$14,515.00
|
$20.37 M
|
$19.23 M
|
$7.31 M
|
$1.41 M
|
| Selling & Marketing Expenses |
$0.00
|
$13.51 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$19.23 M
|
$13.53 M
|
$20.37 M
|
$19.23 M
|
$7.31 M
|
$1.41 M
|
| Other Expenses |
$0.00
|
-$4.35 M
|
-$940,312.82
|
-$2.98 M
|
-$1.07 M
|
-$411,438.78
|
| Operating Expenses |
$48.49 M
|
$62.07 M
|
$114.69 M
|
$97.59 M
|
$29.36 M
|
$16.44 M
|
| Cost And Expenses |
$48.49 M
|
$62.07 M
|
$114.69 M
|
$97.59 M
|
$29.36 M
|
$16.44 M
|
| Interest Income |
$4.45 M
|
$5,199.00
|
$1.56 M
|
$97,670.00
|
$109,837.00
|
$154,652.00
|
| Interest Expense |
$0.00
|
$0.00
|
$21,032.00
|
$6,909.14
|
$6,433.98
|
$7,689.09
|
| Depreciation & Amortization |
$0.00
|
$988,000.00
|
$1.01 M
|
$640,980.00
|
$221,053.00
|
$114,610.00
|
| EBITDA |
-$22.45 M |
-$58.37 M |
-$111.31 M |
-$204.93 M |
-$118.21 M |
-$24.78 M |
| EBITDA Ratio |
-0.86
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.86
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$7.05 M
|
$2.69 M
|
-$403,662.00
|
-$103.21 M
|
-$89.07 M
|
-$8.41 M
|
| Income Before Tax |
-$15.41 M
|
-$59.38 M
|
-$116.12 M
|
-$204.94 M
|
-$119.37 M
|
-$24.46 M
|
| Income Before Tax Ratio |
-0.59
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$223,000.00
|
$120,000.00
|
$297,517.00
|
$266,473.00
|
$934,459.00
|
-$442,485.29
|
| Net Income |
-$15.63 M
|
-$59.50 M
|
-$116.42 M
|
-$205.21 M
|
-$120.30 M
|
-$24.02 M
|
| Net Income Ratio |
-0.6
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.28 |
-1.08 |
-14.5 |
-25 |
-14.45 |
-3.02 |
| EPS Diluted |
-0.28 |
-1.08 |
-14.5 |
-25 |
-14.45 |
-3.02 |
| Weighted Average Shares Out |
$55.21 M
|
$55.07 M
|
$55.04 M
|
$52.27 M
|
$53.94 M
|
$55.82 M
|
| Weighted Average Shares Out Diluted |
$55.21 M
|
$55.07 M
|
$55.04 M
|
$52.27 M
|
$53.94 M
|
$55.82 M
|
| Link |
|
|
|
|
|
|
